Pharmaceutical composition and administrations thereof

Pharmaceutical composition and administrations thereof

Provided are pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor). In one embodiment a pharmaceutical composition comprises a solid dispersion of amorphous or substantially amorphous ivacafto...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: DAS LAURA, DOKOU ELENI, ISRANI MEGHNA JAI, KUZMISSION ANDREW G, KNEZIC DRAGUTIN, JAMZAD SHAHLA
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator DAS LAURA
DOKOU ELENI
ISRANI MEGHNA JAI
KUZMISSION ANDREW G
KNEZIC DRAGUTIN
JAMZAD SHAHLA
description Provided are pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor). In one embodiment a pharmaceutical composition comprises a solid dispersion of amorphous or substantially amorphous ivacaftor in an amount of about 15 to about 47 percent by weight of the composition; sucralose in an amount of about 2 percent by weight of the composition; croscarmellose sodium in an amount from about 3 to about 6 percent of by weight of the composition; sodium lauryl sulfate (SLS) in an amount of about 0 to about 0.5 percent by weight of the composition; colloidal silicon dioxide in an amount of about 1 percent by weight of the composition; magnesium stearate in an amount of about 1.5 percent by weight of the composition; and mannitol in an amount of about 42 to about 77.5 percent of by weight of the composition. The pharmaceutical compositions are useful in the treatment of CFTR mediated diseases, such as cystic fibrosis.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ607494A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ607494A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ607494A3</originalsourceid><addsrcrecordid>eNrjZDALyEgsyk1MTi0tyUxOzFFIzs8tyC_OLMnMz1NIzEtRSEzJzczLLC4pSgQJFSuUZKQWpean8TCwpiXmFKfyQmluBjk31xBnD93Ugvz41OICoIF5qSXxflFmBuYmliaOxgQVAAD9DC1x</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Pharmaceutical composition and administrations thereof</title><source>esp@cenet</source><creator>DAS LAURA ; DOKOU ELENI ; ISRANI MEGHNA JAI ; KUZMISSION ANDREW G ; KNEZIC DRAGUTIN ; JAMZAD SHAHLA</creator><creatorcontrib>DAS LAURA ; DOKOU ELENI ; ISRANI MEGHNA JAI ; KUZMISSION ANDREW G ; KNEZIC DRAGUTIN ; JAMZAD SHAHLA</creatorcontrib><description>Provided are pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor). In one embodiment a pharmaceutical composition comprises a solid dispersion of amorphous or substantially amorphous ivacaftor in an amount of about 15 to about 47 percent by weight of the composition; sucralose in an amount of about 2 percent by weight of the composition; croscarmellose sodium in an amount from about 3 to about 6 percent of by weight of the composition; sodium lauryl sulfate (SLS) in an amount of about 0 to about 0.5 percent by weight of the composition; colloidal silicon dioxide in an amount of about 1 percent by weight of the composition; magnesium stearate in an amount of about 1.5 percent by weight of the composition; and mannitol in an amount of about 42 to about 77.5 percent of by weight of the composition. The pharmaceutical compositions are useful in the treatment of CFTR mediated diseases, such as cystic fibrosis.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20150424&amp;DB=EPODOC&amp;CC=NZ&amp;NR=607494A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20150424&amp;DB=EPODOC&amp;CC=NZ&amp;NR=607494A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DAS LAURA</creatorcontrib><creatorcontrib>DOKOU ELENI</creatorcontrib><creatorcontrib>ISRANI MEGHNA JAI</creatorcontrib><creatorcontrib>KUZMISSION ANDREW G</creatorcontrib><creatorcontrib>KNEZIC DRAGUTIN</creatorcontrib><creatorcontrib>JAMZAD SHAHLA</creatorcontrib><title>Pharmaceutical composition and administrations thereof</title><description>Provided are pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor). In one embodiment a pharmaceutical composition comprises a solid dispersion of amorphous or substantially amorphous ivacaftor in an amount of about 15 to about 47 percent by weight of the composition; sucralose in an amount of about 2 percent by weight of the composition; croscarmellose sodium in an amount from about 3 to about 6 percent of by weight of the composition; sodium lauryl sulfate (SLS) in an amount of about 0 to about 0.5 percent by weight of the composition; colloidal silicon dioxide in an amount of about 1 percent by weight of the composition; magnesium stearate in an amount of about 1.5 percent by weight of the composition; and mannitol in an amount of about 42 to about 77.5 percent of by weight of the composition. The pharmaceutical compositions are useful in the treatment of CFTR mediated diseases, such as cystic fibrosis.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDALyEgsyk1MTi0tyUxOzFFIzs8tyC_OLMnMz1NIzEtRSEzJzczLLC4pSgQJFSuUZKQWpean8TCwpiXmFKfyQmluBjk31xBnD93Ugvz41OICoIF5qSXxflFmBuYmliaOxgQVAAD9DC1x</recordid><startdate>20150424</startdate><enddate>20150424</enddate><creator>DAS LAURA</creator><creator>DOKOU ELENI</creator><creator>ISRANI MEGHNA JAI</creator><creator>KUZMISSION ANDREW G</creator><creator>KNEZIC DRAGUTIN</creator><creator>JAMZAD SHAHLA</creator><scope>EVB</scope></search><sort><creationdate>20150424</creationdate><title>Pharmaceutical composition and administrations thereof</title><author>DAS LAURA ; DOKOU ELENI ; ISRANI MEGHNA JAI ; KUZMISSION ANDREW G ; KNEZIC DRAGUTIN ; JAMZAD SHAHLA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ607494A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2015</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>DAS LAURA</creatorcontrib><creatorcontrib>DOKOU ELENI</creatorcontrib><creatorcontrib>ISRANI MEGHNA JAI</creatorcontrib><creatorcontrib>KUZMISSION ANDREW G</creatorcontrib><creatorcontrib>KNEZIC DRAGUTIN</creatorcontrib><creatorcontrib>JAMZAD SHAHLA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DAS LAURA</au><au>DOKOU ELENI</au><au>ISRANI MEGHNA JAI</au><au>KUZMISSION ANDREW G</au><au>KNEZIC DRAGUTIN</au><au>JAMZAD SHAHLA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Pharmaceutical composition and administrations thereof</title><date>2015-04-24</date><risdate>2015</risdate><abstract>Provided are pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor). In one embodiment a pharmaceutical composition comprises a solid dispersion of amorphous or substantially amorphous ivacaftor in an amount of about 15 to about 47 percent by weight of the composition; sucralose in an amount of about 2 percent by weight of the composition; croscarmellose sodium in an amount from about 3 to about 6 percent of by weight of the composition; sodium lauryl sulfate (SLS) in an amount of about 0 to about 0.5 percent by weight of the composition; colloidal silicon dioxide in an amount of about 1 percent by weight of the composition; magnesium stearate in an amount of about 1.5 percent by weight of the composition; and mannitol in an amount of about 42 to about 77.5 percent of by weight of the composition. The pharmaceutical compositions are useful in the treatment of CFTR mediated diseases, such as cystic fibrosis.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_NZ607494A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Pharmaceutical composition and administrations thereof
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T20%3A29%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DAS%20LAURA&rft.date=2015-04-24&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ607494A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true